To assess the effects of pioglitazone and rosiglitazone on fasting and postprandial low-density lipoprotein (LDL) size and subclasses in patients with Type 2 diabetes
Effect of pioglitazone versus insulin glargine on cardiac size, function, and measures of fluid rete...
This study compared the effects of administering rosiglitazone (RSG) vs pioglitazone (PIO) oil cardi...
Thiazolidinediones are antidiabetic agents that decrease insulin resistance. Emerging evidence indic...
Rosiglitazone may increase cardiovascular risk in patients with type 2 diabetes. Yet, its effects on...
Rosiglitazone may increase cardiovascular risk in patients with type 2 diabetes. Yet, its effects on...
tive effects of pioglitazone and rosiglita-zone on liporpotein sub-fractions in patients with type 2...
The thiazolidinediones, rosiglitazone and pioglitazone are used in the treatment of Type 2 diabetes ...
We evaluated study population characteristics and treatment effects on blood lipids between studies ...
OBJECTIVE — Increased postprandial lipemia is part of diabetic dyslipidemia and is associ-ated with ...
OBJECTIVE — To characterize potential differences in glycemic control, plasma lipid level, and weigh...
Abstract—We evaluated study population characteristics and treatment effects on blood lipids between...
OBJECTIVE — To compare effects of different oral hypoglycemic drugs as first-line therapy on lipopro...
Although the metabolic effects of the thiazolidinediones have been well studied, there is a lack of ...
The aim of the study was to evaluate the effect of pioglitazone and glibenclamide on lipid profile a...
The aim of the study was to evaluate the effect of pioglitazone and glibenclamide on lipid profile a...
Effect of pioglitazone versus insulin glargine on cardiac size, function, and measures of fluid rete...
This study compared the effects of administering rosiglitazone (RSG) vs pioglitazone (PIO) oil cardi...
Thiazolidinediones are antidiabetic agents that decrease insulin resistance. Emerging evidence indic...
Rosiglitazone may increase cardiovascular risk in patients with type 2 diabetes. Yet, its effects on...
Rosiglitazone may increase cardiovascular risk in patients with type 2 diabetes. Yet, its effects on...
tive effects of pioglitazone and rosiglita-zone on liporpotein sub-fractions in patients with type 2...
The thiazolidinediones, rosiglitazone and pioglitazone are used in the treatment of Type 2 diabetes ...
We evaluated study population characteristics and treatment effects on blood lipids between studies ...
OBJECTIVE — Increased postprandial lipemia is part of diabetic dyslipidemia and is associ-ated with ...
OBJECTIVE — To characterize potential differences in glycemic control, plasma lipid level, and weigh...
Abstract—We evaluated study population characteristics and treatment effects on blood lipids between...
OBJECTIVE — To compare effects of different oral hypoglycemic drugs as first-line therapy on lipopro...
Although the metabolic effects of the thiazolidinediones have been well studied, there is a lack of ...
The aim of the study was to evaluate the effect of pioglitazone and glibenclamide on lipid profile a...
The aim of the study was to evaluate the effect of pioglitazone and glibenclamide on lipid profile a...
Effect of pioglitazone versus insulin glargine on cardiac size, function, and measures of fluid rete...
This study compared the effects of administering rosiglitazone (RSG) vs pioglitazone (PIO) oil cardi...
Thiazolidinediones are antidiabetic agents that decrease insulin resistance. Emerging evidence indic...